Dr. Henry Rosevear looks at how practices have changed since he entered into medicine and what these changes mean for urologists.
Modern Medicine News
After attending an industry dinner, urologist Henry Rosevear, MD, came away with an appreciation for the role of health care economics in bringing a product to market.
While CMS has demonstrated an ability to listen to providers’ concerns about QPP implementation, many issues still need to be addressed and urologists must continue to be vocal.
There are several options for saving for retirement, but first develop a good understanding of how these retirement accounts work to get the most out of your savings.
Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Nirmish Singla, MD, offers career planning tips to urology residents who may be approaching the end of their training.
Henry Rosevear, MD, discusses the pros and cons of S corporations and why he decided to create one.
Urology Times reached out to three urologists (selected randomly and asked them each the following question: How will immunotherapy change the future of bladder Ca care?
The chances of needing long-term disability insurance are higher than you might think and can be worth the expense
Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more